Patent intelligence · US
US 8293803
Retinoid compounds and their use
Retinoid compounds and their use
Patent details — US 8293803
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 23, 2012
- Expiration
- Oct 18, 2032
- Applicant
- Reinnervate Limited
- Claims
- 12
- CPC classes
- A61K, A61K31/216, A61K31/235, A61P
Quick answer
US 8293803 (Retinoid compounds and their use) is held by Reinnervate Limited. Status: granted. Granted Oct 23, 2012. Expires Oct 18, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Reinnervate Limited
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/216, A61K31/235, A61P, A61P17/02, A61P17/10
More from Reinnervate Limited
Related pharmaceutical patents in our USPTO index.
-
US 12390512
Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae
granted -
US 11033623
Magnetic stem cell therapy for lesions
granted -
US 10472381
Sialic acid derivatives
granted -
US 10265396
Magnetic extracellular matrix
granted -
US 9539228
Composition containing lysine as a nutritional supplement or treatment in the case of herpes
granted -
US 8309071
Foamy viral envelope genes
granted -
US 8268792
Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases
granted
Related coverage
Frequently asked questions
What is US patent 8293803?
US 8293803 (Retinoid compounds and their use) is held by Reinnervate Limited. Status: granted. Granted Oct 23, 2012. Expires Oct 18, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8293803?
Reinnervate Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does US 8293803 expire?
Our index shows an expiration date of Oct 18, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.